Skip to main content
TipRanks
Go Ultimate75% OFF

Aspire Biopharma Holdings (ASBP) Ratios

194 Followers

Aspire Biopharma Holdings Ratios

ASBP's free cash flow for Q2 2026 was $-2.12M. For the 2026 fiscal year, ASBP's free cash flow was increased by $0.00 and operating cash flow was $-2.12M. See a summary of the company’s cash flow.

Financial ratios
RatiosDec 25Dec 24Dec 23Dec 22Dec 21
Liquidity Ratios
Current Ratio0.170.090.203.621.00
Quick Ratio0.140.090.203.621.00
Cash Ratio0.130.000.001.640.00
Solvency Ratio-2.14-7.4314.390.300.01
Operating Cash Flow Ratio-0.65-0.16-1.62-4.64-0.00
Short-Term Operating Cash Flow Coverage-3.56-0.21-52.74-50.37-0.00
Net Current Asset Value$ -6.38M$ -1.54M$ -322.11K$ -10.02M$ -475.00
Leverage Ratios
Debt-to-Assets Ratio1.068.560.000.000.81
Debt-to-Equity Ratio-0.22-0.820.000.00-502.31
Debt-to-Capital Ratio-0.28-4.640.000.001.00
Long-Term Debt-to-Capital Ratio0.000.000.000.000.00
Financial Leverage Ratio-0.21-0.101.021.04-617.31
Debt Service Coverage Ratio-1.14-31.07271.85119.41-0.11
Interest Coverage Ratio-2.273.46-149.450.000.00
Debt to Market Cap0.010.000.000.000.00
Interest Debt Per Share6.630.540.000.000.01
Net Debt to EBITDA-0.03-0.110.00-0.14-9.36
Profitability Margins
Gross Profit Margin-1.87%0.00%0.00%0.00%0.00%
EBIT Margin-312016.95%0.00%0.00%0.00%0.00%
EBITDA Margin-182712.72%0.00%0.00%0.00%0.00%
Operating Profit Margin-312016.95%0.00%0.00%0.00%0.00%
Pretax Profit Margin-394725.06%0.00%0.00%0.00%0.00%
Net Profit Margin-394725.06%0.00%0.00%0.00%0.00%
Continuous Operations Profit Margin-394725.06%0.00%0.00%0.00%0.00%
Net Income Per EBT100.00%100.00%100.00%100.00%100.00%
EBT Per EBIT126.51%405.90%-333.13%-342.09%99.98%
Return on Assets (ROA)-1865.68%-8471.58%22.34%1.11%-8.69%
Return on Equity (ROE)383.93%814.04%22.80%1.16%5363.16%
Return on Capital Employed (ROCE)308.11%200.55%-6.84%-0.33%5364.21%
Return on Invested Capital (ROIC)395.26%-48.30%-6.84%-0.33%-4.80%
Return on Tangible Assets-1865.68%-8471.58%22.34%1.11%-8.69%
Earnings Yield-10.34%-0.13%0.01%0.01%-0.00%
Efficiency Ratios
Receivables Turnover0.000.000.000.000.00
Payables Turnover0.010.000.000.000.00
Inventory Turnover0.020.000.000.000.00
Fixed Asset Turnover0.000.000.000.000.00
Asset Turnover0.000.000.000.000.00
Working Capital Turnover Ratio-0.000.000.000.000.00
Cash Conversion Cycle-43976.610.000.000.000.00
Days of Sales Outstanding0.000.000.000.000.00
Days of Inventory Outstanding14625.420.000.000.000.00
Days of Payables Outstanding58602.030.000.000.000.00
Operating Cycle14625.420.000.000.000.00
Cash Flow Ratios
Operating Cash Flow Per Share-3.29-0.38-0.01-0.01-0.00
Free Cash Flow Per Share-3.29-0.38-0.01-0.01-0.00
Dividend Paid and CapEx Coverage Ratio0.000.00-217702.33-352196.500.00
Capital Expenditure Coverage Ratio0.000.00-217702.33-352196.500.00
Operating Cash Flow Coverage Ratio-3.56-0.21-52.74-50.37-0.00
Operating Cash Flow to Sales Ratio-793.850.000.000.000.00
Free Cash Flow Yield-2.08%-0.00%-0.00%-0.00%-0.00%
Valuation Ratios
Price-to-Earnings (P/E) Ratio-9.67-759.497486.0015633.30-392149.17
Price-to-Sales (P/S) Ratio38181.400.000.000.000.00
Price-to-Book (P/B) Ratio-37.14-6181.981706.80180.63-21031578.95
Price-to-Free Cash Flow (P/FCF) Ratio-48.10-35902.35-51166.94-37063.99-38423076.92
Price-to-Operating Cash Flow Ratio-48.10-35902.35-51166.94-37063.99-38423076.92
Price-to-Earnings Growth (PEG) Ratio0.192.5768.62-5.620.00
Enterprise Value Multiple-20.93-817.645757.6715632.05-392081.58
Enterprise Value237.18M9.52B33.42B52.21B9.99B
EV to EBITDA-20.93-817.645757.6715632.05-392081.58
EV to Sales38242.810.000.000.000.00
EV to Free Cash Flow-48.17-35907.11-51166.96-37063.66-38423994.60
EV to Operating Cash Flow-48.17-35907.11-51166.96-37063.66-38423994.60
Tangible Book Value Per Share-4.27-2.230.262.28-0.00
Shareholders’ Equity Per Share-4.27-2.230.262.28-0.00
Tax and Other Ratios
Effective Tax Rate0.00-0.000.000.000.00
Revenue Per Share0.000.000.000.000.00
Net Income Per Share-16.38-18.170.060.03-0.00
Tax Burden1.001.001.001.001.00
Interest Burden1.271.081.001.000.00
Research & Development to Revenue148.970.000.000.000.00
SG&A to Revenue2971.180.000.000.000.00
Stock-Based Compensation to Revenue2278.500.000.000.000.00
Income Quality0.200.20-0.15-0.429.36

Currency in USD